Smith & Nephew plc (SNN) Analyst/Investor Day Transcript

Smith & Nephew plc (SNN) Analyst/Investor Day Transcript

Seeking Alpha • Dec 12, 2025

Smith & Nephew boosts 2025 cashflow forecast and unveils medium-term targets

British medical products maker Smith & Nephew raised its 2025 free cash flow forecast to around $800 million and unveiled new medium-term targets ahead of its Capital Markets Day Event on Monday.

Reuters • Dec 8, 2025

Smith & Nephew nudges up guidance and unveils new strategic plan

Smith & Nephew PLC (LSE:SN) has launched a new corporate strategy designed to give stronger returns for shareholders, alongside issuing medium-term financial targets through to 2028, alongside updated guidance for 2025 and a provisional outlook for accelerating growth in 2026. The knee and hip replacement company named the strategy RISE, as it will drive improved financial and operational performance by focusing on four pillars: Reaching more patients, Innovation, Scaling through investment, and efficient Execution.

Proactive Investors • Dec 8, 2025

Smith & Nephew's ambitious growth plans get sceptical reaction from analysts

Smith & Nephew PLC's (LSE:SN) new strategic plan and 2028 outlook look ambitious, City analysts said, but have been received with some heavy dashes of scepticism. UBS, which kept its rating on the shares at 'neutral' and set a 1,290p price target versus a last close at 1,265p, said treating the targets with caution is warranted as the company has achieved growth of over 6% only six times in the past 20 years, "and only two times in the past 15 years (one of which was 2021 COVID recovery)".

Proactive Investors • Dec 8, 2025

Smith & Nephew steadies expectations as investors look to December

For a business built on orthopaedics and wound care, Smith & Nephew PLC (LSE:SN) has given investors a fair bit of whiplash. Its third-quarter update sent the shares down about 10% after organic revenue growth came in weaker than hoped and, crucially, slowed from the second quarter despite earlier guidance that it would accelerate.

Proactive Investors • Nov 13, 2025

Smith & Nephew plunges as weaker US knees

Smith & Nephew PLC (LSE:SN) shares were the worst faller on the FTSE 100 on Thursday morning, down 12% after reporting lower revenues than expected Third-quarter revenue growth came in at 5.0%, below consensus expectations of 6.1%, with orthopaedics slower than forecast due to a weaker performance in US knee replacement surgeries, with sport medicine also softer than expected. UBS analysts said: "while guidance was reiterated, we think this will disappoint versus expectations".

Proactive Investors • Nov 6, 2025

Smith & Nephew plc (SNN) Q3 2025 Sales Call Transcript

Smith & Nephew plc ( SNN ) Q3 2025 Sales Call November 6, 2025 3:30 AM EST Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Reynolds-Clark - RBC Capital Markets, Research Division Veronika Dubajova - Citigroup Inc., Research Division Hassan Al-Wakeel - Barclays Bank PLC, Research Division Graham Doyle - UBS Investment Bank, Research Division Kane Slutzkin - Deutsche Bank AG, Research Division Julien Dormois - Jefferies LLC, Research Division David Adlington - JPMorgan Chase & Co, Research Division Presentation Operator Good morning. Thank you for attending today's Smith & Nephew Quarter 3 2025 Trading Report.

Seeking Alpha • Nov 6, 2025

Smith & Nephew: Expensive Valuations And Muted Growth May Dampen Upcoming Q3 Earnings Release

Smith & Nephew plc maintains a 'Hold' rating due to valuation concerns and limited near-term upside despite recent operational improvements. Sequential growth across all business units and a 100 basis point trading margin expansion support management's confidence in achieving full-year guidance. Technical analysis reveals significant resistance at $38 and $40-$42, with bearish intermediate signals suggesting potential price weakness over the next 6-10 months.

Seeking Alpha • Nov 5, 2025

Smith+Nephew comparative study1 shows  PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published, first-of-its-kind comparative study of single-use negative pressure wound therapy (sNPWT) devices in orthopedic and cardiovascular surgery.

GlobeNewsWire • Oct 27, 2025

UFC® and Smith+Nephew announce multi-year extension of partnership

Smith+Nephew to continue as UFC's Preferred Sports Medicine Technology Partner Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, and UFC the world's premier mixed martial arts organization, have announced a multi-year extension of their landmark worldwide marketing partnership forged in 2024.  Under the renewal, Smith+Nephew will continue as UFC's Preferred Sports Medicine Technology Partner, a designation it received as UFC's inaugural partner in that category, to activate its brand around some of UFC's biggest events.

GlobeNewsWire • Oct 22, 2025